Novocure Valuation
NVCR Stock | USD 19.69 1.81 10.12% |
At this time, the firm appears to be undervalued. Novocure secures a last-minute Real Value of $27.86 per share. The latest price of the firm is $19.69. Our model forecasts the value of Novocure from analyzing the firm fundamentals such as Profit Margin of (0.26) %, current valuation of 1.65 B, and Return On Equity of -0.4 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Novocure's valuation include:
Price Book 5.3624 | Enterprise Value 1.7 B | Enterprise Value Ebitda (6.92) | Price Sales 3.3486 | Forward PE 909.0909 |
Undervalued
Today
Please note that Novocure's price fluctuation is not too volatile at this time. Calculation of the real value of Novocure is based on 3 months time horizon. Increasing Novocure's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Novocure stock is determined by what a typical buyer is willing to pay for full or partial control of Novocure. Since Novocure is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Novocure Stock. However, Novocure's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. Historical | Market 19.69 | Real 27.86 | Target 56.57 | Hype 19.77 | Naive 20.22 |
The intrinsic value of Novocure's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Novocure's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Novocure helps investors to forecast how Novocure stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Novocure more accurately as focusing exclusively on Novocure's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Novocure's intrinsic value based on its ongoing forecasts of Novocure's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Novocure's closest peers.
Novocure Cash |
|
Novocure Valuation Trend
Novocure's real value is important for investors to make better decisions and a more accurate overall view of Novocure's financial worth over time. Using both Novocure's enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Novocure Total Value Analysis
Novocure is now forecasted to have valuation of 1.65 B with market capitalization of 1.93 B, debt of 596.24 M, and cash on hands of 948.52 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Novocure fundamentals before making equity appraisal based on enterprise value of the companyTakeover Price | Market Cap | Debt Obligations | Cash |
1.65 B | 1.93 B | 596.24 M | 948.52 M |
Novocure Investor Information
About 87.0% of the company shares are owned by institutional investors. The company has Price/Earnings (P/E) ratio of 721.15. Novocure recorded a loss per share of 1.39. The entity had not issued any dividends in recent years. Based on the measurements of operating efficiency obtained from Novocure's historical financial statements, Novocure is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.Novocure Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Novocure has an asset utilization ratio of 44.44 percent. This connotes that the Company is making $0.44 for each dollar of assets. An increasing asset utilization means that Novocure is more efficient with each dollar of assets it utilizes for everyday operations.Novocure Ownership Allocation
Novocure maintains a total of 108.2 Million outstanding shares. The majority of Novocure outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Novocure to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Novocure. Please pay attention to any change in the institutional holdings of Novocure as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Novocure Profitability Analysis
The company reported the previous year's revenue of 509.34 M. Net Loss for the year was (207.04 M) with profit before overhead, payroll, taxes, and interest of 423.58 M.About Novocure Valuation
The stock valuation mechanism determines Novocure's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Novocure based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Novocure. We calculate exposure to Novocure's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Novocure's related companies.Last Reported | Projected for Next Year | ||
Gross Profit | 381.1 M | 222.2 M | |
Pretax Profit Margin | (0.38) | (0.40) | |
Operating Profit Margin | (0.46) | (0.48) | |
Net Loss | (0.41) | (0.43) | |
Gross Profit Margin | 0.75 | 0.49 |
Novocure Growth Indicators
Investing in growth stocks can be very risky. If the company such as Novocure does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Common Stock Shares Outstanding | 106.4 M | |
Quarterly Earnings Growth Y O Y | -0.06 | |
Forward Price Earnings | 909.0909 |
Novocure Current Valuation Indicators
Novocure's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Novocure's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Novocure, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Novocure's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Novocure's worth.Additional Tools for Novocure Stock Analysis
When running Novocure's price analysis, check to measure Novocure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novocure is operating at the current time. Most of Novocure's value examination focuses on studying past and present price action to predict the probability of Novocure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novocure's price. Additionally, you may evaluate how the addition of Novocure to your portfolios can decrease your overall portfolio volatility.